Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Inflammatory Bowel Diseases

  Free Subscription


27.11.2023

5 Aliment Pharmacol Ther
1 Am J Gastroenterol
2 BMC Gastroenterol
1 Clin Gastroenterol Hepatol
1 Dis Colon Rectum
2 Gastroenterol Hepatol
2 Gastroenterology
5 Inflamm Bowel Dis
2 J Crohns Colitis
1 J Gastroenterol
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. DESAI A, Regueiro M, Kochhar GS
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed        

  2. SOHN J
    Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2023;58.
    PubMed        

  3. REZAZADEH ARDABILI A, Janssen L, Mujagic Z
    Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
    Aliment Pharmacol Ther. 2023;58.
    PubMed        

  4. CHANG HC, Gau SY
    Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2023;58.
    PubMed        

  5. BASSOTTI G, Villanacci V, Maconi G
    Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
    Aliment Pharmacol Ther. 2023;58.
    PubMed        


    Am J Gastroenterol

  6. KAYAL M, Deepak P, Beniwal-Patel P, Raffals L, et al
    Changes in Therapy Are Not Associated with Increased Remission in Patients with Crohn's Disease of the Pouch.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002599.
    PubMed         Abstract available


    BMC Gastroenterol

  7. YOON H, Park YS, Shin JE, Ye BD, et al
    Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea.
    BMC Gastroenterol. 2023;23:405.
    PubMed         Abstract available

  8. TANG Z, Sun S, Ji M, Shi P, et al
    Long-term outcomes after enterostomy for very early-onset inflammatory bowel disease with interleukin-10 signaling deficiency.
    BMC Gastroenterol. 2023;23:404.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  9. MAGRO F, Protic M, De Hertogh G, Chan LS, et al
    Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
    Clin Gastroenterol Hepatol. 2023 Nov 20:S1542-3565(23)00948.
    PubMed         Abstract available


    Dis Colon Rectum

  10. BOOTH AT, Curran T
    Perioperative Malnutrition.
    Dis Colon Rectum. 2023;66:1528-1530.
    PubMed         Abstract available


    Gastroenterol Hepatol

  11. MANUEL BENITEZ J, Suarez-Ferrer C, Calafat M, Baston-Rey I, et al
    Paediatric to adult transition programme in inflammatory bowel disease, why do we need it?
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00469.
    PubMed        

  12. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Bertoletti F, et al
    Duration of smoking cessation in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00470.
    PubMed         Abstract available


    Gastroenterology

  13. ANANTHAKRISHNAN AN, Adler J, Chachu KA, Nguyen NH, et al
    AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease.
    Gastroenterology. 2023;165:1367-1399.
    PubMed         Abstract available

  14. DAVE M, Luther J, Briggs F
    Time to Include Inflammatory Bowel Disease as a Notifiable Disease?
    Gastroenterology. 2023 Nov 7:S0016-5085(23)05223.
    PubMed        


    Inflamm Bowel Dis

  15. DISTANTE M, Rotulo S, Ranalli M, Pedace E, et al
    Clusters of Disease Activity and Early Risk Factors of Clinical Course of Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 23:izad275. doi: 10.1093.
    PubMed         Abstract available

  16. ROSHANOV PS, Khanna R
    The Use of Placebo in Clinical Trials of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2023 Nov 21:izad281. doi: 10.1093.
    PubMed        

  17. SHAW VR, Byun J, Pettit RW, Hou JK, et al
    An Atlas Characterizing the Shared Genetic Architecture of Inflammatory Bowel Disease with Clinical and Behavioral Traits.
    Inflamm Bowel Dis. 2023 Nov 20:izad269. doi: 10.1093.
    PubMed         Abstract available

  18. FERNANDES SR, Bernardo S, Saraiva S, Rita Goncalves A, et al
    Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis.
    Inflamm Bowel Dis. 2023 Nov 20:izad272. doi: 10.1093.
    PubMed         Abstract available

  19. SIGALL BONEH R, Westoby C, Oseran I, Sarbagili-Shabat C, et al
    The Crohn's Disease Exclusion Diet: A Comprehensive Review of Evidence, Implementation Strategies, Practical Guidance, and Future Directions.
    Inflamm Bowel Dis. 2023 Nov 18:izad255. doi: 10.1093.
    PubMed         Abstract available


    J Crohns Colitis

  20. MEHTA S
    Intestinal Failure: A Small but Imperfectly Phenotyped Complication of Crohn's Disease.
    J Crohns Colitis. 2023 Nov 21:jjad154. doi: 10.1093.
    PubMed        

  21. ROCHA CH, Walshe M, Birch S, Sabic K, et al
    Clinical predictors of early and late endoscopic recurrence following ileocolonic resection in Crohn's disease.
    J Crohns Colitis. 2023 Nov 17:jjad186. doi: 10.1093.
    PubMed         Abstract available


    J Gastroenterol

  22. SUN S, Lv B
    The antiferroptotic effect of indigo on ulcerative colitis.
    J Gastroenterol. 2023 Nov 23. doi: 10.1007/s00535-023-02063.
    PubMed         Abstract available


    Scand J Gastroenterol

  23. ZHANG Y, Jiang W, Xu C, Tian J, et al
    The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
    Scand J Gastroenterol. 2023 Nov 22:1-11. doi: 10.1080/00365521.2023.2283387.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.